Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 4Phase 1/2 2

Status

Active not recruiting 3Terminated 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Skin Neoplasms 1Plasmablastic Lymphoma 1Melanoma 1Lymphomatoid Granulomatosis 1Lymphoma, Primary Effusion 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Glioblastoma 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Burkitt Lymphoma 1

Interventions

Cisplatin 1519Carboplatin 1420Cyclophosphamide 1360Gemcitabine 1235Bevacizumab 1226Paclitaxel 1211Radiotherapy 1176Docetaxel 1080pembrolizumab 1028Oxaliplatin 936Capecitabine 900Fluorouracil 833Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 666Etoposide 660Irinotecan 622Leucovorin 575Pemetrexed 510Drug Therapy 493Cetuximab 483Trastuzumab 469Cytarabine 466Magnetic Resonance Spectroscopy 458Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 408Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × varlilumab × Clear all
NCT03688178 2026-05-22

DERIVe

Duke University

Phase 2 Active not recruiting
43 enrolled
CNS

Glioblastoma

NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT04941287 2025-05-23

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
57 enrolled 13 charts
Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT02302339 2019-09-06

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Celldex Therapeutics

Phase 2 Terminated
132 enrolled 16 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡